<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2701">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04367077</url>
  </required_header>
  <id_info>
    <org_study_id>B04-03</org_study_id>
    <nct_id>NCT04367077</nct_id>
  </id_info>
  <brief_title>MultiStem Administration for COVID-19 Induced ARDS (MACoVIA)</brief_title>
  <acronym>MACoVIA</acronym>
  <official_title>A Phase 2/3 Study to Assess the Safety and Efficacy of MultiStemÂ® Therapy in Subjects With Acute Respiratory Distress Syndrome (ARDS) Due to Coronavirus Disease (COVID-19)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Athersys, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Athersys, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter investigation featuring an open-label lead-in followed by a double blinded,
      randomized, placebo-controlled Phase 2/3 part to evaluate the safety and efficacy of
      MultiStem therapy in subjects with moderate to severe Acute Respiratory Distress Syndrome
      (ARDS) due to COVID-19.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 28, 2020</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ventilator-Free Days</measure>
    <time_frame>Day 0 through Day 28.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability as measured by the incidence of treatment-emergent adverse events as assessed by CTCAE v5.0.</measure>
    <time_frame>Day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ranked hierarchical composite outcome of alive and ventilator-free</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator-free days</measure>
    <time_frame>Day 0 through Day 60</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>ARDS</condition>
  <arm_group>
    <arm_group_label>MultiStem</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MultiStem</intervention_name>
    <description>intravenous infusion</description>
    <arm_group_label>MultiStem</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>intravenous infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Diagnosis of new acute-onset moderate to severe ARDS, as defined by the Berlin criteria and
        Clinical diagnosis of COVID-19,

        Exclusion Criteria:

        Moribund subject who, in the opinion of the Investigator, is not expected to survive at
        least 48 hours and End-stage severe chronic lung disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony Ting, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Athersys, Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Athersys Clinical Trials Group</last_name>
    <phone>2164263597</phone>
    <email>macovia@athersys.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Athersys Investigational Site 103</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Athersys Clinical Trials Group</last_name>
      <phone>216-426-3597</phone>
      <email>macovia@athersys.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Athersys Investigational Site 101</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Athersys Clinical Trials Group</last_name>
      <phone>216-426-3597</phone>
      <email>macovia@athersys.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Athersys Investigational Site 102</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Athersys Clinical Trials Group</last_name>
      <phone>216-426-3597</phone>
      <email>macovia@athersys.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>April 27, 2020</study_first_submitted>
  <study_first_submitted_qc>April 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2020</study_first_posted>
  <last_update_submitted>September 28, 2020</last_update_submitted>
  <last_update_submitted_qc>September 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID19</keyword>
  <keyword>respiratory distress</keyword>
  <keyword>adult stem cells</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

